Low-dose intravenous and subcutaneous CIS43LS monoclonal antibody for protection against malaria (VRC 612 Part C): a phase 1, adaptive trial
Kirsten E. Lyke(University of Maryland, Baltimore), William Edward Witt, Andrezza Campos Chagas(Walter Reed Army Institute of Research), LaSonji A. Holman(National Institutes of Health), Judy Stein(National Institutes of Health), Andrew J. McDougal(National Institutes of Health), Jennifer L. Winkler, Kwang Low(National Institutes of Health), Bob C. Lin(National Institutes of Health), Olga Trofymenko(National Institutes of Health), Lesia Dropulic(National Institutes of Health), Manjula Basappa(National Institutes of Health), Colleen Boyce, Kaitlin Mason(University of Maryland, Baltimore), Zonghui Hu(National Institutes of Health), Sudhaunshu Joshi(University of Maryland, Baltimore), Nancy Greenberg, Emily E. Coates(National Institutes of Health), Kathleen Strauss(University of Maryland, Baltimore), Mercy Guech(National Institutes of Health), Sandra Vazquez(National Institutes of Health), Edmund V. Capparelli(University of California San Diego), Somia P. Hickman(National Institutes of Health), Alyson Kwon, Azza H. Idris(National Institutes of Health), Ana Raquel Da Costa, Martin R. Gaudinski(National Institute of Allergy and Infectious Diseases), Shirley St. George, Mike Castro(National Institutes of Health), Ingelise J. Gordon(National Institute of Allergy and Infectious Diseases), Sandeep Narpala(National Institutes of Health), Leonid Serebryannyy(National Institutes of Health), Robert A. Seder(National Institutes of Health), Susan Holian, Matthew Adams(University of Maryland, Baltimore), Andrea A. Berry(University of Maryland, Baltimore), Mark O’Callahan(National Institutes of Health), Julie E. Ledgerwood(Vaccine Research Institute of San Diego), Myra Happe(National Institute of Allergy and Infectious Diseases), Lu Wang(Children's Hospital of Philadelphia), Richard L Wu(National Institute of Allergy and Infectious Diseases), Larisa Strom(National Institute of Allergy and Infectious Diseases), Jittawadee Murphy(Walter Reed Army Institute of Research), Biraj Shrestha(University of Maryland, Baltimore), Cheryl Young(National Institutes of Health), Floreliz Mendoza(National Institutes of Health), Brenda Dorsey, Adrian B. McDermott, Sarah H. Plummer(National Institutes of Health), Nina M. Berkowitz(National Institutes of Health)
Cited by 42
Related Papers
The Role of Tumoral FOXP3 on Cell Proliferation, Migration, and Invasion in Gastric Cancer
|Cellular Physiology and Biochemistry|2017|4.1k
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
|New England Journal of Medicine|2020|2.7k
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
|Nature|2020|1.6k
T-cell quality in memory and protection: implications for vaccine design
|Nature reviews. Immunology|2008|1.6k
Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major
|Nature Medicine|2007|1.4k